IDiyas

For the Inventor, By the Inventor

Ware, United Kingdom

Ian James Collins

USPTO Granted Patents = 41


 

Average Co-Inventor Count = 5.5

ph-index = 9

Forward Citations = 234(Granted Patents)


Location History:

  • Ware, GB (1997 - 2008)
  • London, GB (2013)
  • Redhill, GB (2006 - 2016)
  • Sutton, GB (2011 - 2023)

Company Filing History:

goldMedal20 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal20 out of 262 
 
Cancer Research Technology Limited
 patents
bronzeMedal9 out of 123 
 
Astex Therapeutics Limited
 patents
4. 9 out of 51 
 
The Institute of Cancer Research: Royal Cancer Hospital
 patents
5. 1 out of 1 
 
Merck & Dohme Limited
 patent
6. 1 out of 76 
 
Merck Frosst Canada & Co.
 patents
where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...
Loading Chart...
Loading Chart...
41 patents (USPTO):
1. 11787792 - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereof (2023-10-17),
2. 10259806 - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof (2019-04-16),
3. 9765059 - 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use (2017-09-19),
4. 9663503 - 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof (2017-05-30),
5. 9403797 - 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use (2016-08-02),
6. 9283226 - Pyrazole derivatives as protein kinase modulators (2016-03-15),
7. 9040540 - 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use (2015-05-26),
8. 9006430 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein (2015-04-14),
9. 8809336 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors (2014-08-19),
10. 8796293 - Purine and deazapurine derivatives as pharmaceutical compounds (2014-08-05),
11. 8691806 - Pyrazole derivatives as protein kinase modulators (2014-04-08),
12. 8618121 - 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors (2013-12-31),
13. 8546407 - Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors (2013-10-01),
14. 8541461 - Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators (2013-09-24),
15. 8530468 - Bicyclylaryl-aryl-amine compounds and their use (2013-09-10),

Title: Innovator Spotlight: Ian James Collins, a Prolific Inventor in Therapeutic Compounds

Introduction:

Ian James Collins from Ware, GB, is a distinguished inventor with 41 patents to his name. His groundbreaking work in the field of therapeutic compounds has earned him recognition globally.

Latest Patents:

One of Ian James Collins' latest patents is for 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile compounds. These compounds have shown promise in inhibiting Checkpoint Kinase 1 (CHK1) kinase function, making them valuable in the treatment of various diseases, including cancer.

Career Highlights:

Ian James Collins has made significant contributions during his tenure at Merck Sharp & Dohme Corporation and Cancer Research Technology Limited. His innovative approach to developing therapeutic compounds has led to groundbreaking advancements in medical science.

Collaborations:

Throughout his career, Ian James Collins has collaborated with esteemed professionals in the field. Some of his notable coworkers include Timothy Harrison and Robert George Boyle. These collaborations have been instrumental in bringing his inventions to fruition.

Conclusion:

Ian James Collins stands out as a visionary inventor, with a remarkable portfolio of patents in the realm of therapeutic compounds. His dedication to advancing medical research and his collaborative spirit have solidified his position as a leading figure in the innovation landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…